Is Merck Paying Peanuts to Viralytics for Full Access to Its Oncolytic Immunotherapy Drug Candidate?
The Merck DealThe competition between the leading checkpoint inhibitor cancer drugs Opdivo/Yervoy (Bristol Myers Squibb Co (BMY US) ) and Keytruda...
259 Views
Nektar: New Pathways To Smarter Deals?
Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with...
241 Views
Biosimilar Battlefield: An Update
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
418 Views
Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
305 Views
Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
469 Views